These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28472307)

  • 1. Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.
    Soulie C; Grudé M; Descamps D; Amiel C; Morand-Joubert L; Raymond S; Pallier C; Bellecave P; Reigadas S; Trabaud MA; Delaugerre C; Montes B; Barin F; Ferré V; Jeulin H; Alloui C; Yerly S; Signori-Schmuck A; Guigon A; Fafi-Kremer S; Haïm-Boukobza S; Mirand A; Maillard A; Vallet S; Roussel C; Assoumou L; Calvez V; Flandre P; Marcelin AG;
    J Antimicrob Chemother; 2017 Aug; 72(8):2351-2354. PubMed ID: 28472307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
    Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotypic resistance profiles of HIV-2-treated patients in West Africa.
    Charpentier C; Eholié S; Anglaret X; Bertine M; Rouzioux C; Avettand-Fenoël V; Messou E; Minga A; Damond F; Plantier JC; Dabis F; Peytavin G; Brun-Vézinet F; Ekouevi DK;
    AIDS; 2014 May; 28(8):1161-9. PubMed ID: 24583671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study.
    Edén A; Nilsson S; Hagberg L; Fuchs D; Zetterberg H; Svennerholm B; Gisslén M
    J Infect Dis; 2016 Dec; 214(12):1822-1825. PubMed ID: 27683820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid.
    Cinque P; Presi S; Bestetti A; Pierotti C; Racca S; Boeri E; Morelli P; Carrera P; Ferrari M; Lazzarin A
    AIDS Res Hum Retroviruses; 2001 Mar; 17(5):377-83. PubMed ID: 11282006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study.
    Loubet P; Charpentier C; Visseaux B; Borbor A; Nuta C; Adu E; Chapplain JM; Baysah M; Tattevin P; Yazdanpanah Y; Descamps D
    J Antimicrob Chemother; 2015; 70(6):1881-4. PubMed ID: 25698771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.
    Cusini A; Vernazza PL; Yerly S; Decosterd LA; Ledergerber B; Fux CA; Rohrbach J; Widmer N; Hirschel B; Gaudenz R; Cavassini M; Klimkait T; Zenger F; Gutmann C; Opravil M; Günthard HF;
    J Acquir Immune Defic Syndr; 2013 Jan; 62(1):28-35. PubMed ID: 23018371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
    Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
    Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical and virological correlation between the cerebrospinal fluid and blood of HIV-infected children].
    Sáez-Llorens X; Castrejón de Wong MC; Castaño E; de Suman O; Báez de Ulloa C; Redondo W; Espino M
    Rev Med Panama; 2001; 26():13-8. PubMed ID: 16161718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
    J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
    Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
    J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The significance of low-level plasma HIV viral load on COBAS TaqMan HIV-1 assays for patients with undetectable plasma viral load on COBAS Amplicor monitor version 1.5.
    Manavi K
    HIV Clin Trials; 2008; 9(4):283-6. PubMed ID: 18753122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India.
    Dravid AN; Natrajan K; Kulkarni MM; Saraf CK; Mahajan US; Kore SD; Rathod NM; Mahajan US; Wadia RS
    Medicine (Baltimore); 2018 Feb; 97(8):e9969. PubMed ID: 29465595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.
    De Luca A; Vendittelli M; Baldini F; Di Giambenedetto S; Trotta MP; Cingolani A; Bacarelli A; Gori C; Perno CF; Antinori A; Ulivi G
    Antivir Ther; 2004 Aug; 9(4):583-93. PubMed ID: 15456090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells.
    Joseph SB; Kincer LP; Bowman NM; Evans C; Vinikoor MJ; Lippincott CK; Gisslén M; Spudich S; Menezes P; Robertson K; Archin N; Kashuba A; Eron JJ; Price RW; Swanstrom R
    Clin Infect Dis; 2019 Sep; 69(8):1345-1352. PubMed ID: 30561541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study.
    Assoumou L; Charpentier C; Recordon-Pinson P; Grudé M; Pallier C; Morand-Joubert L; Fafi-Kremer S; Krivine A; Montes B; Ferré V; Bouvier-Alias M; Plantier JC; Izopet J; Trabaud MA; Yerly S; Dufayard J; Alloui C; Courdavault L; Le Guillou-Guillemette H; Maillard A; Amiel C; Vabret A; Roussel C; Vallet S; Guinard J; Mirand A; Beby-Defaux A; Barin F; Allardet-Servent A; Ait-Namane R; Wirden M; Delaugerre C; Calvez V; Chaix ML; Descamps D; Reigadas S;
    J Antimicrob Chemother; 2017 Jun; 72(6):1769-1773. PubMed ID: 28333232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse White Matter Signal Abnormalities on Magnetic Resonance Imaging Are Associated With Human Immunodeficiency Virus Type 1 Viral Escape in the Central Nervous System Among Patients With Neurological Symptoms.
    Kugathasan R; Collier DA; Haddow LJ; El Bouzidi K; Edwards SG; Cartledge JD; Miller RF; Gupta RK
    Clin Infect Dis; 2017 Apr; 64(8):1059-1065. PubMed ID: 28329096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.
    Rawson T; Muir D; Mackie NE; Garvey LJ; Everitt A; Winston A
    J Infect; 2012 Sep; 65(3):239-45. PubMed ID: 22522289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.
    Di Yacovo MS; Moltó J; Ferrer E; Curran A; Else L; Gisslén M; Clotet B; Tiraboschi JM; Niubò J; Vila A; Zetterberg H; Back D; Podzamczer D
    J Antimicrob Chemother; 2015 May; 70(5):1513-6. PubMed ID: 25608583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study.
    Assoumou L; Descamps D; Yerly S; Dos Santos G; Marcelin AG; Delaugerre C; Morand-Joubert L; Ruffault A; Izopet J; Plantier JC; Pakianather S; Montes B; Chaix ML; Wirden M; Costagliola D; Masquelier B;
    J Antimicrob Chemother; 2013 Jun; 68(6):1400-5. PubMed ID: 23404192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.